Base excess and hematocrit predict response to indomethacin in very low birth weight infants with patent ductus arteriosus

Table 1 Baseline characteristics of newborns with patent ductus arteriosus by treatment outcome

Variable^a	Responders^b N = 62 (68%)	Non-responders N = 29 (32%)	P value
Maternal age (y) [mean (SD)]	25.7 (6.6)	24.4 (6.6)	0.35
Race / ethnicity [n (%)]
White	5 (8.06)	2 (6.90)	1.00
Black	39 (62.90)	19 (65.52)
Hispanic	18 (29.03)	8 (27.59)
Sex [n (%)]
Female	28 (45.16)	15 (51.72)	0.56
Gestational age (wk) [median (range)]	26.0 (22.0–30.0)	24.0 (21.0–28.0)	0.004*
GA (wk) [n (%)]
< 28	48 (77.42)	26 (89.66)	0.16
PROM duration (h) [median (range)]	0 (0–360)	0 (0–168)	0.39
Antenatal steroid [n (%)]
No	11 (17.74)	7 (24.14)	0.48
Chorioamnionitis^c [n (%)]
Yes	7 (11.48)	7 (24.14)	0.13
Vasopressors use [n (%)]
Yes	23 (37.10)	12 (41.38)	0.70
Multiple gestation [n (%)]
Yes	9 (14.52)	4 (13.79)	1.00
No	53 (85.48)	25 (86.21)
BW (g) [mean (SD)]	870 (246)	738 (232)	0.02^*
Apgar at 5th min [n (%)]
0–3	3 (4.84)	5 (17.86)	0.02^*
4–6	14 (22.58)	11 (39.29)
> 6	45 (72.58)	12 (42.86)
Surfactant use [n (%)]
Yes	60 (99.77)	29 (100.00)	1.00
Admission temperature (°C) [median (range)]	37 (34–38)	37 (33–38)	0.80
DOL at start of treatment (d) [median (range)]	4 (1–52)	5 (2–44)	0.40

SD standard deviation, GA gestational age, PROM premature rupture of membranes, BW birth weight, DOL day of life
^*Significant (P < 0.05)
^aFor simplicity and readability, we have listed only one of the 2 possible options for binary variables
^bInfants were considered responders if there was successful ductal closure following indomethacin treatment
^cVariable had missing data

ISSN: 1824-7288